GS 5734

Drug Profile

GS 5734

Alternative Names: Captisol®-enabled GS 5734; GS-5734

Latest Information Update: 09 Nov 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases
  • Class Adenine nucleotides; Antivirals; Small molecules
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ebola virus infections

Most Recent Events

  • 28 Jun 2016 National Institute of Allergy and Infectious Diseases plans the phase II PREVAIL IV trial for Ebola virus infections in USA and Liberia (IV) (NCT02818582)
  • 01 Jun 2016 Phase-II clinical trials in Ebola virus infections in USA and Liberia (IV) (NCT02818582)
  • 21 Oct 2015 GS 5734 is available on a Compassionate basis for the treatment of Ebola virus infections in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top